CABP2 Patient Registry and Natural History Study
Launched by UNIVERSITY MEDICAL CENTER GOETTINGEN · Nov 7, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The CABP2 Patient Registry and Natural History Study is a research project aimed at understanding a specific type of hearing impairment known as CABP2-related Auditory Synaptopathy. This study will gather important information about patients who have been genetically diagnosed with this condition, which can help researchers learn more about how it affects hearing over time. The study is currently recruiting participants of all ages and genders, as long as they have a genetic diagnosis showing changes in both copies of the CABP2 gene and have undergone hearing tests.
To be eligible for this study, participants must have a confirmed genetic diagnosis related to the CABP2 gene and have hearing impairment. Those who have been diagnosed with other genetic conditions affecting hearing will not be included. If you choose to participate, you can expect to contribute to valuable research that may improve understanding and treatment options for individuals with this type of hearing loss. Your involvement could help shape future care for others facing similar challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A molecular genetic diagnosis involving biallelic variants in CAPB2 and audiometry
- Exclusion Criteria:
- • Patients with evidence of non-CABP2 molecular genetic diagnoses
About University Medical Center Goettingen
The University Medical Center Göttingen (UMG) is a leading academic institution in Germany, renowned for its commitment to advancing medical research and education. As a sponsor of clinical trials, UMG leverages its extensive expertise and state-of-the-art facilities to facilitate innovative research that aims to improve patient care and treatment outcomes. With a focus on interdisciplinary collaboration, UMG fosters partnerships across various medical fields, ensuring a comprehensive approach to clinical investigation. Its dedication to ethical standards and patient safety underscores its role in translating scientific discoveries into effective therapeutic solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Göttingen, , Germany
Patients applied
Trial Officials
Tobias Moser, MD
Study Director
University Medical Center Goettingen
Bernd Wollnik, MD
Principal Investigator
University Medical Center Goettingen
Nicola Strenzke, MD
Principal Investigator
University Medical Center Goettingen
Barbara Vona, PhD
Principal Investigator
University Medical Center Goettingen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported